Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

MCRB 11.22.2024

Full Press ReleaseSEC FilingsOur MCRB Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.16.2025 - Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
  • 01.09.2025 - Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
PDF Version

CAMBRIDGE, Mass.,Nov. 22, 2024(GLOBE NEWSWIRE) --Seres Therapeutics, Inc.(Nasdaq: MCRB), a leading live biotherapeutics company, today announced thatEric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36thAnnual Healthcare Conference onDecember 3, 2024, at4:30 p.m. ET.

A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website atwww.serestherapeutics.comand will be available for replay following the event.

About Seres TherapeuticsSeres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWSTTM, the first FDA-approved orally administered microbiome therapeutic, and which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visitwww.serestherapeutics.com.

Investor and Media Contacts:IR@serestherapeutics.com

Carlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com

This press release was published by a CLEAR® Verified individual.

Primary Logo

Source: Seres Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com